AU2002339158A1 - 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors - Google Patents

2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors

Info

Publication number
AU2002339158A1
AU2002339158A1 AU2002339158A AU2002339158A AU2002339158A1 AU 2002339158 A1 AU2002339158 A1 AU 2002339158A1 AU 2002339158 A AU2002339158 A AU 2002339158A AU 2002339158 A AU2002339158 A AU 2002339158A AU 2002339158 A1 AU2002339158 A1 AU 2002339158A1
Authority
AU
Australia
Prior art keywords
factor
propanamides
oxopyrrolidin
sulfonylamino
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002339158A
Other languages
English (en)
Inventor
Alan David Borthwick
Matthew Campbell
Chuen Chan
Henry Anderson Kelly
Nigel Paul King
Savvas Kleanthous
Andrew Mcmurtrie Mason
Stefan Senger
Paul William Smith
Nigel Stephen Watson
Robert John Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2002339158A1 publication Critical patent/AU2002339158A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2002339158A 2001-11-16 2002-11-13 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors Abandoned AU2002339158A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0127568.4A GB0127568D0 (en) 2001-11-16 2001-11-16 Chemical compounds
GB0127568.4 2001-11-16
PCT/GB2002/005134 WO2003043981A1 (en) 2001-11-16 2002-11-13 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors

Publications (1)

Publication Number Publication Date
AU2002339158A1 true AU2002339158A1 (en) 2003-06-10

Family

ID=9925931

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002339158A Abandoned AU2002339158A1 (en) 2001-11-16 2002-11-13 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors

Country Status (9)

Country Link
US (1) US7179835B2 (OSRAM)
EP (1) EP1444201B1 (OSRAM)
JP (1) JP2005521641A (OSRAM)
AT (1) ATE372982T1 (OSRAM)
AU (1) AU2002339158A1 (OSRAM)
DE (1) DE60222459T2 (OSRAM)
ES (1) ES2292820T3 (OSRAM)
GB (1) GB0127568D0 (OSRAM)
WO (1) WO2003043981A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
GB0314299D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
JP2006527732A (ja) * 2003-06-19 2006-12-07 グラクソ　グループ　リミテッド Ｘａ因子の阻害剤としての３−スルホニルアミノ−ピロリジン−２−オン誘導体
GB0314373D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
JP6050238B2 (ja) 2011-10-19 2016-12-21 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
HRP20190245T1 (hr) * 2013-04-26 2019-04-05 Sanofi Tartratna sol [(s)-2-[metil-3-(2-okso-pirolidin-1-il)-benzensulfonilamino]-3-(4-metil piperazin-1 -il)-3-okso-propril]amida 5-kloro-tiofen-2-karboksilne kiseline

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
DE4121947A1 (de) * 1991-07-03 1993-01-07 Basf Ag 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
US5703208A (en) 1994-06-17 1997-12-30 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
US5932733A (en) 1994-06-17 1999-08-03 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors
JPH10503176A (ja) 1994-06-17 1998-03-24 コーバス インターナショナル， インコーポレイテッド 酵素インヒビターとしての３−アミノ−２−オキソ−１−ピペリジン酢酸誘導体
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
AU7604196A (en) 1995-10-30 1997-05-22 Merck & Co., Inc. Novel inhibitors of peptide binding to mhc class ii proteins
WO1998016523A2 (en) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
US6602864B1 (en) 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
PL333921A1 (en) 1996-12-13 2000-01-31 Rhone Poulenc Rorer Pharma N-(heteroalkyl)-azaheterocyclyamides of sulphonic acids or other n-(heteroalkyl)-azaheterocyclylamide compounds
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US6525042B1 (en) 1997-09-30 2003-02-25 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
ZA988967B (en) 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
JP2002536437A (ja) * 1999-02-09 2002-10-29 ブリストル−マイヤーズ スクイブ カンパニー ＦＸａのラクタム抑制剤および方法
EP1206449A1 (en) 1999-07-26 2002-05-22 Bristol-Myers Squibb Company Lactam inhibitors of hepatitis c virus ns3 protease
HK1050005A1 (zh) * 1999-09-13 2003-06-06 三维药物公司 氮杂环烷酮丝氨酸蛋白酶抑制剂
AU2001255408A1 (en) * 2000-04-14 2001-10-30 Corvas International, Inc. Tetrahydro-azepinone derivatives as thrombin inhibitors

Also Published As

Publication number Publication date
ES2292820T3 (es) 2008-03-16
WO2003043981A1 (en) 2003-05-30
GB0127568D0 (en) 2002-01-09
US7179835B2 (en) 2007-02-20
JP2005521641A (ja) 2005-07-21
EP1444201B1 (en) 2007-09-12
ATE372982T1 (de) 2007-09-15
DE60222459D1 (en) 2007-10-25
US20050004119A1 (en) 2005-01-06
DE60222459T2 (de) 2008-06-12
EP1444201A1 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
AP1699A (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
YU5503A (sh) Nesteroidni supresori zapaljenja
AU2055500A (en) Aromatic amides
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
AU2001280438A1 (en) Substituted heterocyclic amides
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
WO2006002099A3 (en) Factor xa inhibitors
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
IL143545A (en) Thrombin inhibitors and pharmaceutical compositions containing them
WO2005005389A3 (en) Malonamide derivatives
DE602005016297D1 (de) Antithrombotische diamide
HRP20090159T1 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
DE602005019316D1 (en) Aromatische etherderivate als thrombin-hemmer
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
MY136859A (en) Pyrrolidine derivatives as factor xa inhibitors
WO2006063113A3 (en) Ureas as factor xa inhibitors
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
AU2001282871A1 (en) Antithrombotic agents
ATE443044T1 (de) Tace inhibitoren
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
WO2004030664A3 (en) New compounds for the inhibition of undesired cell proliferation and use thereof
WO2005049604A3 (en) Antithrombotic aromatic ethers
DE60222459D1 (en) 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamide als factor xa inhibitoren

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase